UNRESECTABLE SOLID NEOPLASM
Clinical trials for UNRESECTABLE SOLID NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE SOLID NEOPLASM trials appear
Sign up with your email to follow new studies for UNRESECTABLE SOLID NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise in battling recurrent ovarian cancer
Disease control OngoingThis study tested a combination of two drugs, veliparib and topotecan, in 88 patients with solid tumors or ovarian cancer that returned after initial treatment. The goal was to find the safest dose and see how well the drugs shrink tumors. While the treatment aims to control the …
Matched conditions: UNRESECTABLE SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Experimental drug combo shows promise for Tough-to-Treat cancers
Disease control OngoingThis study tests a new drug called TRC102 (methoxyamine) combined with standard chemotherapy (cisplatin and pemetrexed) in people with advanced solid tumors or mesothelioma that has not responded to prior treatment. The goal is to see if TRC102 can make cancer cells more sensitiv…
Matched conditions: UNRESECTABLE SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New hope for Hard-to-Treat cancers: targeted immunotherapy shows promise
Disease control OngoingThis study tests whether the immunotherapy drug nivolumab can help control cancer in 16 people with advanced solid tumors that have spread or can't be removed by surgery. Participants must have a specific genetic change (ARID1A mutation) and a protein marker (CXCL13) in their tum…
Matched conditions: UNRESECTABLE SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New Vaccine-Immunotherapy combo targets multiple cancers in early trial
Disease control OngoingThis phase 1 trial tests a vaccine (p53MVA) that trains the immune system to attack cancer cells with a p53 mutation, given together with the immunotherapy drug pembrolizumab (Keytruda). The study includes 11 people with advanced solid tumors like lung, head and neck, liver, kidn…
Matched conditions: UNRESECTABLE SOLID NEOPLASM
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Rare cancer hope: immune drug shows promise in phase 2 trial
Disease control OngoingThis study tested a drug called pembrolizumab in 157 people with rare cancers that had spread or couldn't be removed. The drug works by helping the body's immune system attack the cancer. The main goal was to see how many patients were alive and their cancer hadn't grown after 27…
Matched conditions: UNRESECTABLE SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC